[1] Pham TND, Le DH, Dao DVB, et al. Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi Minh City, Vietnam – a community-based seroprevalence study. Lancet Reg Health West Pac, 2023; 30, 100620. doi:  10.2139/ssrn.4132341
[2] Burki T. WHO's 2024 global hepatitis report. Lancet Infect Dis, 2024; 24, e362−3.
[3] Li QR, Sun BZ, Zhuo Y, et al. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol, 2022; 13, 1034968. doi:  10.3389/fimmu.2022.1034968
[4] Cheng ST, Hu JL, Ren JH, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol, 2021; 74, 522−34.
[5] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol, 2017; 66, 460−2. doi:  10.1016/j.jhep.2016.09.028
[6] Wong DKH, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int, 2017; 37, 995−1001. doi:  10.1111/liv.13346
[7] Mak LY, Seto WK, Fung J, et al. New biomarkers of chronic hepatitis B. Gut Liver, 2019; 13, 589−95. doi:  10.5009/gnl18425
[8] Yoshida K, Desbiolles A, Feldman SF, et al. Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10, 397 individual participants. Clin Gastroenterol Hepatol, 2021; 19, 46-60. e8.
[9] Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol, 2019; 70, 615−25. doi:  10.1016/j.jhep.2018.11.030
[10] To WP, Mak LY, Wong DKH, et al. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. J Viral Hepat, 2019; 26, 1473−80. doi:  10.1111/jvh.13191
[11] Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology, 2019; 157, 1518-29. e3.
[12] Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol, 2013; 58, 427−33. doi:  10.1016/j.jhep.2012.10.025
[13] Tada T, Kumada T, Toyoda H, et al. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol, 2018; 33, 918−25.
[14] Wang J, Shen T, Huang XB, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016; 65, 700−10.
[15] Chang XJ, Sun C, Chen Y, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol, 2019; 25, 4764−78.
[16] Deng W, Zhang ZY, Li XX, et al. A retrospective study of pregnancy and fetal outcomes in mothers with hepatitis C viremia. Biomed Environ Sci, 2025; 38, 829−39.
[17] Zhang M, Li GD, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int, 2020; 14, 212−24.
[18] van Bömmel F, van Bömmel A, Krauel A, et al. Serum HBV RNA as a predictor of peginterferon Alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J Infect Dis, 2018; 218, 1066−74.
[19] Vecchi A, Rossi M, Tiezzi C, et al. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B. Gut, 2024; 73, 1737−48.
[20] Li YY, Yang SQ, Li C, et al. Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study. Virol J, 2024; 21, 231.
[21] Cao WH, Zhang YQ, Zhang ZY, et al. Lipid-related insulin resistance indices for the diagnosis of non-alcoholic fatty liver disease in Chinese adults. Biomed Environ Sci, 2026; 39, 171−82.
[22] Hsu YC, Nguyen MH, Mo LR, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther, 2019; 49, 107−15.
[23] Tian YK, Yu HB, Chen J. Emerging serum biomarkers for chronic hepatitis B: focus on serum HBV RNA and HBcrAg. J Clin Transl Hepatol, 2025; 13, 766−75.
[24] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018; 67, 1560−99.
[25] Ma H, Zhang HH, Wei L. Frequency of T-cell FoxP3+ Treg and CD4+/CD8+ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J (Engl), 2013; 126, 267−73.
[26] Jiang SW, Guo SM, Huang Y, et al. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis. Hepatol Int, 2024; 18, 892−903.
[27] Zhang Y, Wang LF, Chen J, et al. Traditional and novel virologic markers for functional cure and HBeAg loss with pegylated interferon in chronic hepatitis B: a systematic review and meta-analysis. J Clin Transl Hepatol, 2026; 14, 159−67.
[28] Wang SY, Zhang ZY, Li XX, et al. Clinical characteristics of SARS-CoV-2 infection in patients with chronic hepatitis B during interferon antiviral therapy. Biosaf Health, 2025; 7, 377−83.
[29] Su QD, Shen LP, Guo XQ, et al. Genomic characteristics of 12 HBV-I strains in the 2020 national HBV serosurvey in China. Biosaf Health, 2025; 7, 17−25.